<i>In Silico</i> Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder
Alireza Sharafshah(Guilan University of Medical Sciences), Kenneth Blum(Desert Institute For Spine Care), Rossano Kepler Alvim Fiorelli(Hospital Universitário Gaffrée e Guinle), Paul R. Carney(University of Missouri), Edward J. Modestino(Curry College), Eliot L. Gardner(National Institutes of Health), Colin Hanna(Jacobs Institute), David Baron(Mount Sinai Hospital), Jag Khalsa(National Institute on Drug Abuse), Jean Lud Cadet(United States Department of Health and Human Services), Rajendra D. Badgaiyan(Texas Tech University), Rene Cortese(University of Illinois Chicago), Abdalla Bowirrat(Ariel University), Igor Elman(Cambridge Health Alliance), Albert Pinhasov, Brian Fuehrlein(Yale University), Catherine A. Dennen(Thomas Jefferson University Hospital), Sergio L. Schmidt(Universidade Federal do Estado do Rio de Janeiro), Mark S. Gold(Washington University in St. Louis), Kai-Uwe Lewandrowski(Desert Institute For Spine Care), Gene Jack Wang(National Institute on Alcohol Abuse and Alcoholism), Aryeh R Pollack(NeuroGenetic Pharmaceuticals (United States)), Jocelyn Ashford(VA Palo Alto Health Care System), Eric R. Braverman(Cornell University), Panayotis K. Thanos(Jacobs Institute)
Cited by 9
Related Papers
Measuring Adiposity in Patients: The Utility of Body Mass Index (BMI), Percent Body Fat, and Leptin
|PLoS ONE|2012|551
Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model
|Journal of Pharmacology and Experimental Therapeutics|2007|218
Naltrexone-induced opiate receptor supersensitivity
|Brain Research|1982|196